This transcript has been edited for clarity. Jacob Sands, MD: Hello. I'm Dr Jacob Sands, a thoracic medical oncologist at the Dana-Farber Cancer Institute. Welcome to Medscape's InDiscussion series on ...
Disparities in lung cancer biomarker testing show barriers that delay diagnosis and treatment for lower-income patients, according to Sandip P. Patel, MD. Patients with lower socioeconomic status were ...
For patients with locally advanced non–small cell lung cancer (NSCLC), multidisciplinary team input optimizes outcomes by tailoring patient care, which is especially important during this era of ...
Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with ...
Racial and ethnic disparities in receipt of guideline concordant treatment for early-stage non-small cell lung cancer in Los Angeles County. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer who received an immunotherapy drug, nivolumab, along with standard ...
Both non-small lung cancer and small cell lung cancer is a disease that now has various therapeutic options available, according to experts. Lung cancer is a disease that now has various therapeutic ...
The EMA has backed new and expanded uses for multiple cancer drugs, signaling a push toward biomarker-driven, earlier-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results